Ian Braithwaite, Ph.D.
Ian Braithwaite brings deep industry and therapeutic experience to his role overseeing project management and operational delivery for Worldwide Clinical Trial’s Immune-Mediated Inflammatory Disorders (IMID), Rare diseases and Oncology business units. He has full accountability for strategic development and execution of all projects conducted by these therapeutic areas, ranging from Immunology/Inflammatory Diseases (rheumatoid arthritis, lupus, psoriasis, IBD, asthma, COPD, etc.), Rare Diseases (for e.g., sickle cell disease, IPF, bullous pemphigoid, cutaneous T-cell lymphoma) and Oncology.
Dr. Braithwaite worked in clinical research for more than 26 years before joining Worldwide in 2015, including serving as Executive Vice President & GM, General Medicine at INC Research, and Global Therapeutic Area Head – General Medicine & Executive Director and Therapeutic Group Head Hematology/Oncology at PPD. Prior to joining the CRO industry, Ian was Director, Clinical Development at AstraZeneca Pharmaceuticals working primarily on Oncology and Immunology/Inflammatory Diseases. He began his career as a clinical research scientist at SmithKline & French after completing his academic studies.
Dr. Braithwaite obtained his Ph.D. in Pharmacology & Therapeutics from the University of Liverpool and Liverpool School of Tropical Medicine, United Kingdom.